The number of planned and ongoing clinical trials (new) for medical devices in September 2022 saw a increase 34% globally when compared with the last 12-month average, according to GlobalData’s medical devices clinical trials database.
The global medical devices market was worth $540.69bn in 2021 and is expected to reach $523.13bn by 2023, according to GlobalData’s analysis.
Medical devices clinical trials by market: Healthcare IT has the most studies
Looking at the new studies by the type of markets, Healthcare IT accounted for the largest proportion (16%) in September 2022, followed by Cardiovascular Devices (12%) and Neurology Devices (10%).
North America tops new clinical trials activity
Comparing the new trials activity in different regions of the globe, North America held the top position with a 54% share during September 2022, followed by Europe with 32%, and Asia-Pacific with 10%.
At the country level, The US had the largest share (48%) of the global medical device clinical trials during the month. In second place was France with a share of 7%, followed by Canada with 7%.
Looking at the share of activity by sponsorship, company-sponsored trials accounted for a 48% share, while institute-sponsored trials held the remaining share.
The monthly average for the last 12 months saw company-sponsored new trials accounting for 47% of new trials and institute-sponsored trials accounting for 53%.
The clinical trials data used for the analysis were extracted from the medical Clinical Trials Database of GlobalData’s Medical Intelligence Center. Medical device clinical trials database covers all clinical trials conducted on medical devices, combination devices, diagnostics, and diagnostic imaging agents covering 16 markets (as per medical device taxonomy). GlobalData tracks clinical trials from six key registries: NCT, UMIN, ACTRN, ChiCTR, EudraCT, and ISRCT. It also monitors universities, company websites, press releases, investor presentations and annual reports to track medical device clinical trials. Industry refers to commercial entities such as private and public companies and their subsidiaries. Non-Industry refers to non-profit making entities including hospitals, universities, government research institutions and non-government research institutions. The information is collected by following systematic research techniques and proprietary methodology. Only planned and ongoing clinical trials are considered for this analysis.